Home / Reports

Reports

EU problematic patent settlements remain at low level

The European Commission’s (EC) fourth monitoring exercise of patent settlements in the pharmaceutical sector has shown the number of potentially problematic settlements under EU antitrust rules remain at a low level. This finding comes despite the fact that the overall number of patent settlements has increased compared to the previous monitoring periods. The EC takes this as evidence that companies can successfully settle patent disputes within the boundaries of the European Union (EU) antitrust rules.

Shortage of HIV/AIDS drugs in South Africa

According to a survey of South African clinics, one in five of them are running short of life-saving HIV/AIDS drugs, affecting nearly half a million people and undermining the success of the world’s largest treatment programme.

OECD report finds reduction in spending on health

Spending on health fell in one of three countries covered by the Organisation for Economic Co-operation and Development (OECD) between 2009 and 2011, with the countries hit hardest by the financial crisis witnessing the biggest cuts.

American-made prescription drugs 76% cheaper when purchased abroad

American patients can make significant savings by buying drugs abroad, according to an analysis carried out by online pharmacy information specialist PharmacyChecker.com.

Biosimilars: what patients need to know

Biosimilars are medicines that are similar to a biological medicine that has already been authorized. Biosimilars are different to generics in that they are not identical to their reference product. This is due to the fact that they are derived from living cells and therefore demonstrate molecular complexity and heterogeneity. For this reason biosimilars must be ‘similar but not identical’ to their reference biological with regards to quality, safety, and efficacy.

Endocrinologists need more data to prescribe biosimilars

Endocrinologists require more clinical trial data for biosimilars compared to other specialists, such as oncologists and gastroenterologists, according to a report from research and advisory firm BioTrends Research Group.

Gastroenterologists unlikely to use infliximab biosimilar

Gastroenterologists are unlikely to prescribe an infliximab biosimilar in their Crohn’s disease or ulcerative colitis patients if it has not been clinically tested in inflammatory bowel diseases, according to a report from a research and advisory firm.

Increased use of generics could save South Africa millions

Increasing the use of generics by 5% could save the healthcare industry and patients in South Africa in excess of Rand 400 million per year, according to a report from the country’s pharmaceutical association.

UK biosimilars uptake lower than in some other EU countries

Use of biosimilars in the UK is lower than might be expected when looking at the use of generics in the UK, and it is lower than in some other European countries.

India’s pharma moving from generics to niche drugs

Indian pharmaceutical companies will increasingly move away from the overcrowded and competitive area of generics and invest more R & D spending in niche drugs, according to a new report.